Activity Overview
This online, on-demand virtual symposium brings together renowned experts in the management of skin cancer. In this educational program, these experts discuss the seminal studies evaluating immune checkpoint inhibitors for cutaneous squamous cell carcinoma (cSCC), with an emphasis on factors that help identify optimal treatment strategies among different available options.
This educational activity is an archive of the live symposium held on February 21, 2026.
Target Audience
This educational activity is directed toward medical oncologists, surgical oncologists, and radiation oncologists who treat patients with cutaneous malignancies. Dermatologists, dermatopathologists, pathologists, fellows, nurse practitioners, physician assistants, nurses, pharmacists, and other health care professionals interested in the treatment of cutaneous malignancies will also be invited to participate.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Evaluate the latest efficacy and safety findings from key trials assessing immune checkpoint inhibitors as monotherapy or in combination regimens for the treatment of advanced cutaneous squamous cell carcinoma (cSCC)
- Assess the mechanistic and clinical differences between PD-1 and PD-L1 inhibitors used for the management of advanced cSCC
- Incorporate patient- and disease-specific characteristics into individualized treatment plans using immunotherapy for advanced cSCC
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here